文献速递前列腺癌男科与性医学

低中危局限期前列腺癌根治性前列腺切除术后男性的睾酮治疗

Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.
PubMed 文献 · J Urol · 2024-09-30

本研究纳入本机构因局限期前列腺癌行根治性前列腺切除术且病理分级分组为1至3组的男性,采用时间依赖Cox模型分析睾酮使用与生化复发的关系。结果显示睾酮使用与生化复发风险非显著降低相关(HR 0.84;95%CI 0.48-1.46;P=0.5),两组5年生化复发概率均低于2%。作者认为睾酮治疗可用于经选择的根治性前列腺切除术后男性,未发现睾酮治疗导致生化复发的证据。

要点

  • 根治性前列腺切除术后使用睾酮与生化复发风险非显著降低相关(HR 0.84;95%CI 0.48-1.46;P=0.5)。
  • 两组5年生化复发概率均低于2%。
  • 作者认为睾酮治疗可用于经选择的根治性前列腺切除术后男性,未发现其导致生化复发的证据。

核心结论

  • 作者认为睾酮治疗可用于经选择的根治性前列腺切除术后男性,未发现睾酮治疗导致生化复发的证据。

研究设计与样本

  • 本研究纳入本机构因局限期前列腺癌行根治性前列腺切除术且病理分级分组为1至3组的男性,共5199例,其中198例在术后任一 time 点接受睾酮治疗,5001例未接受睾酮治疗。
  • 采用时间依赖Cox模型分析至生化复发时间,睾酮使用作为时间依赖协变量,并校正年龄、术前PSA、根治性前列腺切除术时的分级分组及合并症。
  • 采用 landmark 分析:术后18周内最后一次PSA为不可测且截至该时间点未发生生化复发或失访的患者纳入分析,生化复发随访从18周开始。
  • 生化复发定义为根治性前列腺切除术后PSA ≥ 0.1 ng/mL,并第二次确认升高 ≥ 0.1 ng/mL。

主要发现

  • 睾酮组中位年龄为59岁(四分位距55-65),未接受睾酮组为61岁(四分位距56-66)。
  • 睾酮组男性倾向于有更多血管合并症。
  • 在接受睾酮的男性中,49%处方枸橼酸氯米芬,32%接受经皮睾酮,19%接受肌内睾酮。
  • 根治性前列腺切除术后使用睾酮与生化复发风险非显著降低相关(HR 0.84;95%CI 0.48-1.46;P=0.5)。
  • 两组生化复发总体发生率均低,5年生化复发概率均低于2%。

临床怎么用

  • 作者认为睾酮治疗可用于经选择的根治性前列腺切除术后男性,未发现睾酮治疗导致生化复发的证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Testosterone (T) therapy (TTh) in men with T deficiency who have undergone radical prostatectomy (RP) for prostate cancer remains controversial. We aimed to assess the impact of TTh on biochemical recurrence (BCR) rates after RP in men with low-intermediate organ-confined disease. MATERIALS AND METHODS: This study included men who underwent an RP at our institution for organ-confined prostate cancer and had grade groups 1 to 3 on RP pathology. A Cox model was created for time to BCR with T use included as a time-dependent covariate, adjusted for age, preoperative PSA, grade group at RP, and the presence of comorbidities. A landmark analysis was used: Patients were included in the analysis if their last PSA in the 18 weeks postoperatively was undetectable and they had not had BCR or been lost to follow-up by that point, and follow-up for BCR began at 18 weeks. BCR was defined as a PSA ≥ 0.1 ng/mL after RP with a second confirmatory rise ≥ 0.1 ng/mL. RESULTS: The study population included 5199 men after RP, with 198 patients receiving T at any point after RP and 5001 not receiving T. The median age was 59 (interquartile range, 55-65) and 61 (interquartile range, 56-66) years, respectively. Men in the T group tended to present with more vascular comorbidities. For those receiving T, clomiphene citrate was prescribed in 49% of men, 32% received transdermal T, and 19% intramuscular T. We found a nonsignificantly decreased risk of BCR associated with the use of T after RP (hazard ratio, 0.84; 95% CI, 0.48-1.46; P = .5), and overall rates of BCR were low, with probability of BCR at 5 years less than 2% in both groups. CONCLUSIONS: TTh can be given to select men after RP. We found no evidence that administration of TTh after RP causes BCR.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Flores JM, Vertosick EA, Salter CA, et al. Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer. J Urol. 2024. PMID: 39348712. doi:10.1097/JU.0000000000004267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。